Protective murine monoclonal antibodies to Cryptococcus neoformans
- PMID: 1398966
- PMCID: PMC258199
- DOI: 10.1128/iai.60.11.4534-4541.1992
Protective murine monoclonal antibodies to Cryptococcus neoformans
Abstract
Several murine monoclonal antibodies (MAbs) specific for the capsular glucuronoxylomannan of Cryptococcus neoformans were studied for their capacity to confer protection when passively administered to lethally infected mice. The MAb group studied recognized at least three distinct epitopes and included immunoglobulin M (IgM), IgG3, IgG1, and IgA isotypes. The protection model used A/J and BALB/c mice infected intraperitoneally with 10(8) cryptococci. The MAbs were administered either immediately preceding or, in one experiment, 24 to 48 h prior to infection. Protective efficacy was assessed by the ability of passively administered MAbs to prolong the survival of lethally infected mice. Three IgM MAbs, each of which recognized a distinct epitope, were able to prolong survival of lethally infected mice to different extents. A set of IgM, IgG3, IgG1 and IgA MAbs which utilize the same immunoglobulin gene elements and were derived from the same B-cell clone exhibited significant class differences in protective efficacy with IgA, IgG1 > IgM > IgG3. The results confirm that protective MAbs against C. neoformans capsular polysaccharide exist and strongly suggest that both epitope specificity and isotype are important determinants of protective efficacy.
Similar articles
-
Immunoglobulin G3 blocking antibodies to the fungal pathogen Cryptococcus neoformans.J Exp Med. 1996 Apr 1;183(4):1905-9. doi: 10.1084/jem.183.4.1905. J Exp Med. 1996. PMID: 8666947 Free PMC article.
-
Antibodies to Cryptococcus neoformans glucuronoxylomannan enhance antifungal activity of murine macrophages.Infect Immun. 1995 Feb;63(2):573-9. doi: 10.1128/iai.63.2.573-579.1995. Infect Immun. 1995. PMID: 7822024 Free PMC article.
-
Protective and nonprotective human immunoglobulin M monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan manifest different specificities and gene use profiles.Infect Immun. 2004 Aug;72(8):4810-8. doi: 10.1128/IAI.72.8.4810-4818.2004. Infect Immun. 2004. PMID: 15271943 Free PMC article.
-
Cryptococcus neoformans: paradigm for the role of antibody immunity against fungi?Zentralbl Bakteriol. 1996 Aug;284(4):475-95. doi: 10.1016/s0934-8840(96)80001-6. Zentralbl Bakteriol. 1996. PMID: 8899968 Review.
-
Mechanism of action of antibody to capsular polysaccharide in Cryptococcus neoformans infection.Front Biosci. 1998 Feb 1;3:d136-51. doi: 10.2741/a270. Front Biosci. 1998. PMID: 9445465 Review.
Cited by
-
Pathogenic diversity amongst serotype C VGIII and VGIV Cryptococcus gattii isolates.Sci Rep. 2015 Jul 8;5:11717. doi: 10.1038/srep11717. Sci Rep. 2015. PMID: 26153364 Free PMC article.
-
Intranasal IFNgamma extends passive IgA antibody protection of mice against Mycobacterium tuberculosis lung infection.Clin Exp Immunol. 2006 Mar;143(3):467-73. doi: 10.1111/j.1365-2249.2006.03012.x. Clin Exp Immunol. 2006. PMID: 16487246 Free PMC article.
-
Immune response and immunotherapy to Cryptococcus infections.Immunol Res. 2006;35(3):191-208. doi: 10.1385/IR:35:3:191. Immunol Res. 2006. PMID: 17172646 Review.
-
Antibody-mediated protection through cross-reactivity introduces a fungal heresy into immunological dogma.Infect Immun. 2007 Nov;75(11):5074-8. doi: 10.1128/IAI.01001-07. Epub 2007 Aug 20. Infect Immun. 2007. PMID: 17709417 Free PMC article. Review. No abstract available.
-
Antibodies produced in response to Cryptococcus neoformans pulmonary infection in mice have characteristics of nonprotective antibodies.Infect Immun. 2004 Jul;72(7):4271-4. doi: 10.1128/IAI.72.7.4271-4274.2004. Infect Immun. 2004. PMID: 15213172 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous